Research Article
CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer’s Dementia Spectrum
Table 3
Linear regression between amyloid-β ratios and targeted proteomics.
| | CN | MCI | AD | square | Beta coefficient | value | square | Beta coefficient | value | square | Beta coefficient | value |
| Aβ1-42 | IASNTQSR | 0.089 | 0.298 | <0.001 | 0.054 | 0.089 | 0.095 | 0.084 | 0.291 | 0.005 | VAELEDEK | 0.262 | 0.501 | <0.001 | 0.138 | 0.315 | <0.001 | 0.133 | 0.347 | <0.001 | VVSSIEQK | 0.049 | 0.193 | 0.006 | 0.047 | -0.020 | 0.708 | 0.020 | 0.081 | 0.401 | GDSVVYGLR | 0.044 | 0.171 | 0.011 | 0.050 | -0.054 | 0.287 | 0.017 | 0.057 | 0.549 | EPVAGDAVPGPK | 0.328 | 0.564 | <0.001 | 0.179 | 0.371 | <0.001 | 0.238 | 0.481 | <0.001 | QETLPSK | 0.068 | 0.233 | <0.001 | 0.048 | -0.033 | 0.512 | 0.021 | 0.092 | 0.344 | Aβ1-42/1-40 | IASNTQSR | 0.100 | -0.064 | 0.361 | 0.111 | -0.245 | <0.001 | 0.087 | -0.203 | 0.046 | VAELEDEK | 0.100 | 0.063 | 0.330 | 0.058 | -0.031 | 0.558 | 0.060 | -0.084 | 0.370 | VVSSIEQK | 0.116 | -0.146 | 0.029 | 0.134 | -0.287 | <0.001 | 0.142 | -0.303 | 0.001 | GDSVVYGLR | 0.114 | -0.132 | 0.039 | 0.146 | -0.300 | <0.001 | 0.132 | -0.281 | 0.002 | EPVAGDAVPGPK | 0.102 | 0.075 | 0.244 | 0.062 | -0.066 | 0.196 | 0.053 | -0.008 | 0.934 | QETLPSK | 0.101 | -0.070 | 0.278 | 0.125 | -0.262 | <0.001 | 0.110 | -0.242 | 0.010 | Aβ1-42/1-38 | IASNTQSR | 0.092 | -0.064 | 0.360 | 0.107 | -0.255 | <0.001 | 0.059 | -0.162 | 0.115 | VAELEDEK | 0.090 | 0.035 | 0.586 | 0.051 | -0.048 | 0.355 | 0.046 | -0.097 | 0.303 | VVSSIEQK | 0.100 | -0.112 | 0.097 | 0.131 | -0.299 | <0.001 | 0.112 | -0.278 | 0.003 | GDSVVYGLR | 0.112 | -0.153 | 0.018 | 0.141 | -0.308 | <0.001 | 0.100 | -0.250 | 0.007 | EPVAGDAVPGPK | 0.092 | 0.051 | 0.435 | 0.057 | -0.094 | 0.066 | 0.039 | -0.048 | 0.618 | QETLPSK | 0.096 | -0.084 | 0.197 | 0.115 | -0.261 | <0.001 | 0.078 | -0.206 | 0.029 |
|
|
CN: cognitively normal; MCI: mild cognitive impairment; AD: Alzheimer’s disease. values < 0.05 are in bold. |